# Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in China

> **NCT07710872** · PHASE3 · RECRUITING · sponsor: **Sanofi** · enrollment: 4568 (estimated)

## Conditions studied

- Meningococcal Infection
- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA)
- **BIOLOGICAL:** Menhycia® (ACYW135 Meningococcal Conjugate Vaccine [CRM197]) (CanSino Biologics Inc., China)

## Key facts

- **NCT ID:** NCT07710872
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-22
- **Primary completion:** 2028-03-13
- **Final completion:** 2029-07-26
- **Target enrollment:** 4568 (ESTIMATED)
- **Last updated:** 2026-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07710872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07710872, "Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in China". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07710872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*